A cure for HIV would be one of the greatest medical achievements in modern history. But the day a cure is celebrated could also be the day some long-term survivors are told they no longer qualify for the benefits and services that have helped them stay alive.

In our work with long-term survivors, community advisory boards, and discussions about a cure, we have heard a recurring concern that deserves far more policy attention: What if a cure — or durable control, where the virus remains in the body, but at such low levels that it doesn’t cause problems and cannot be transmitted — is treated as proof that support for patients is no longer needed? That fear comes from people who want a cure, but are also wary about what can happen when administrative systems move faster than common sense.

HIV cure research has advanced enough that policymakers should prepare now for its social and administrative consequences, not only its scientific promise. Over the past decade, the field has moved from theory to increasingly sophisticated immunological, gene-based, and combination strategies. A handful of cases have shown that it may be possible to rid the body of HIV, or to reach a point where the virus stays dormant without daily medication.

Rare proof-of-concept cases have shown that durable control without ongoing antiretroviral therapy may be biologically possible, even if those approaches are not scalable for most people living with HIV. That progress makes one policy question urgent: If cure or durable control becomes possible for some people, what happens to the benefits and services on which many people with HIV still depend?

Without safeguards, scientific progress could trigger a benefits cliff. People with HIV could face reassessment or loss of Medicaid, Medicare, Ryan White HIV/AIDS Program services, AIDS Drug Assistance Program support, disability income, housing assistance, and other essential services if administrative systems interpret cure or durable control as evidence that need has ended. This could happen in many ways, including through routine reviews for these programs, such as Medicaid renewals or housing program reviews, or reported changes in medical status or insurance coverage. In a policy environment already marked by paperwork burdens, delayed renewals, and administrative churn, that risk is not abstract.

This issue matters for all people with HIV who rely on safety net programs. The Ryan White HIV/AIDS Program alone served more than 600,000 people with HIV in 2024, representing more than half of people with diagnosed HIV in the United States, but it is especially urgent for long-term survivors. In the U.S., nearly half of people living with HIV are age 50 or older, and roughly one-quarter of that group, about 300,000 people, are long-term survivors who were diagnosed before effective antiretroviral therapy became widely available. Many endured toxic early regimens, profound loss, persistent stigma, interrupted employment, and years of fragmented care. Many are now aging with multiple chronic conditions, disability, trauma, and ongoing financial precarity. For them, cure may reduce treatment burden, but it does not erase the long-term consequences of having lived with HIV.

That distinction is the heart of the problem. A change in viral status is not the same as restored health, work capacity, economic security, or social recovery. If programs rely too narrowly on HIV diagnosis as a proxy for need, then a person who achieves durable control could be treated as though support is no longer necessary even when disability, chronic conditions, and social vulnerability remain unchanged. The concern isn’t new. Community discussions about it intensified after Timothy Ray Brown — the first person documented to be cured of HIV — later faced housing difficulties. His experience became a cautionary example for many in the HIV community: Scientific success does not automatically translate into social or economic security.

Other areas of medicine show why this concern is not hypothetical. For years, many people who qualified for Medicare because of end-stage renal disease lost Medicare coverage 36 months after a successful kidney transplant, even though they still needed lifelong immunosuppressive medications to keep the transplant functioning. Congress later created a limited Medicare immunosuppressive drug benefit to address this gap. But the example is instructive: When policy treats a biomedical milestone as the end of need, patients can face new risks precisely because treatment succeeded. Cancer survivorship offers a related lesson. The completion of active treatment does not necessarily end financial hardship, disability, or the need for ongoing support.

The consequences would not be evenly distributed. They would fall hardest on people already navigating intersecting inequities shaped by age, disability, poverty, housing instability, racism, gender inequality, and stigma. Black and Latino communities, women aging with HIV, transgender people, and others facing structural disadvantage are disproportionately represented among those who rely on public benefits and safety net services. A cure policy that ignores these realities could widen disparities instead of reducing them.

This is also a matter of trust. Long-term survivors remember when policy lagged behind the epidemic and when access to treatment, care, housing, and dignity had to be fought for. If an HIV cure is celebrated while essential supports are reduced or withdrawn, many survivors will hear a familiar message: Progress is valued, but the people who lived long enough to reach it are expendable. That would not only be unjust. It would corrode the community trust that HIV cure research depends on to move forward.

The practical consequences could be significant. Some long-term survivors may reasonably hesitate to embrace cure-related interventions if doing so could jeopardize the services they rely on. When policy creates the perception that getting better leads to losing support, people avoid getting better. Benefits continuity is therefore not just a bureaucratic detail. It is a precondition for cure research to succeed.

Policymakers should act before cure-related classifications become more common, not after people begin losing coverage, housing, or income. Eligibility for health coverage, disability support, housing, and related services should remain anchored to persistent need, not to HIV status alone. Federal and state agencies should work with communities and issue clear guidance that cure or durable control must not automatically trigger loss of eligibility, and systems should provide rapid review pathways and coordinated reassessment practices across Medicaid, Ryan White, and related programs.

Long-term survivors embody both the devastation of the early epidemic and the gains made possible by decades of scientific, clinical, and community effort. They deserve to see a cure, not fear the losses it might bring.

*Ali Ahmed, Ph.D., is a postdoc researcher at Perelman School of Medicine, University of Pennsylvania. Jeff Taylor is director of the HIV+Aging Research Project-Palm Springs and a long-term survivor of HIV. Jeff Berry is the executive director of The Reunion Project, the national alliance of long-term survivors of HIV. *